Premia

Quick links to important sections

Premia

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Premia

Property Description
Active ingredient Estrogens, Conjugated and Medroxyprogesterone Acetate
Form Oral tablet
Pharmacological class Hormone Replacement Therapy (HRT)
Common use Alleviating symptoms of estrogen deficiency
Type Combination medicine (Estrogen + Progestin)

What Type of Medicine is Premia?

Premia is a prescription combination medicine supplied as an oral tablet, classified as Hormone Replacement Therapy (HRT). This medication belongs to the sex hormone combination pharmacological class. It is distinguished as a combined preparation because it contains two distinct active agents. Combination estrogen and progestin therapy is a standard intervention used to address menopausal transition effects, a strategy recognized for its systemic benefits.

Premia’s Composition: Estrogens and Progestin Components

The active ingredients in Premia are Estrogens, Conjugated, and Medroxyprogesterone Acetate (MPA), reflecting a derived estrogen blend and a synthetic progestogen. The Estrogens, Conjugated, component works to replenish diminishing hormone levels. The Medroxyprogesterone Acetate acts as the necessary progestogen, used to mitigate the stimulatory effect of estrogen on the uterine lining, as progestin is required when the uterus is intact. The combination of these two components ensures the therapy provides comprehensive hormonal management.

General Purpose of This Hormone Combination

The general purpose of Premia is to restore hormonal balance and relieve symptoms associated with estrogen deficiency in postmenopausal women with an intact uterus. The mechanism relies on estrogen restoration, which is the basis for symptom relief, coupled with the essential action of the progestin component, which provides necessary endometrial protection. This dual approach is designed to manage menopausal symptoms while protecting the endometrium. This combination is intended for systemic hormonal stabilization.

Regulatory References

  1. MedlinePlus HRT Overview

What side effects are possible with Premia?

Possible Side Effects and Safety Information

The safety profile for this combination hormone replacement therapy is formally documented by regulatory authorities, which classify possible adverse reactions according to both physiological system and observed frequency.

Officially documented adverse reactions are grouped into System-Organ Classes (SOCs), which include Gastrointestinal disorders, Nervous System disorders, Reproductive System and Breast disorders, and Metabolism and Nutrition disorders.

Frequency Classification (As per Regulatory Standards)

Classification Representative Adverse Reactions
Very Common (ge 1/10) Breast pain/tenderness, Headache
Common (ge 1/100 to < 1/10) Nausea, Abdominal pain, Peripheral edema, Vaginal bleeding
Uncommon (ge 1/1,000 to < 1/100) Vomiting, Migraine, Rash
Rare (ge 1/10,000 to < 1/1,000) Venous thromboembolism (VTE), Stroke, Myocardial Infarction

Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies a risk of serious adverse reactions, notably Thromboembolic Events (such as Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction) and certain Neoplasms (including breast and endometrial cancer), with risk potentially increasing with the duration of use.

For women with an intact uterus, the inclusion of Medroxyprogesterone Acetate is a mandatory regulatory requirement to mitigate the risk of Endometrial Hyperplasia associated with unopposed estrogen therapy.

Safety limitations restrict use in individuals with active or a history of Vascular Thromboembolic Disease, known or suspected Estrogen-dependent malignancy, or Severe Hepatic Impairment, as explicitly documented in official labeling.

Irregular uterine bleeding or spotting is an officially recognized effect that is typically more common during the initial months of starting therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the official overdose profile for the combination of Conjugated Estrogens and Medroxyprogesterone Acetate, strictly as documented in governmental regulatory labeling.

Overdosage of this estrogen plus progestin therapy is associated with a specific cluster of clinical manifestations. Documented presentations may include nausea, vomiting, breast tenderness, dizziness, and abdominal pain. Other signs that may occur are drowsiness/fatigue and withdrawal bleeding, which is specifically noted as a potential manifestation in women.


Official Emergency Actions

In the event of suspected over-ingestion, the regulatory documents mandate the discontinuation of the Estrogens, Conjugated and Medroxyprogesterone Acetate combination. Treatment of overdose consists solely of the institution of appropriate symptomatic care.

Medical help should be sought when symptoms of overdose are present to ensure appropriate symptomatic care and evaluation is instituted, as defined by official labeling.


Supportive Care and Antidote Status

The regulatory profile confirms that no specific antidote is documented for reversing the effects of an overdose with this combination therapy. Management is therefore strictly focused on supportive measures based on the patient's clinical presentation.

Therapeutic Uses of Premia

The combination therapy is generally relevant for addressing multiple symptoms related to estrogen deficiency in postmenopausal women who have a uterus. This combination therapy is used across several established therapeutic areas associated with the postmenopausal state.

Premia is commonly used to help manage moderate to severe vasomotor symptoms, which include disruptive hot flashes and night sweats, and localized urogenital atrophy (vaginal dryness and discomfort). Beyond symptom relief, it is also applied when supportive management against the risk of postmenopausal bone loss is appropriate. This covers the management of systemic discomfort, the easing of localized irritative states, and the need for long-term support against skeletal weakening.

It contributes to easing the overall symptom load of these severe manifestations, supporting improved day-to-day comfort. The therapy is relevant for women who still have an intact uterus, and is applied in clinical settings where supportive symptomatic management is appropriate for this patient group.

“The focus is to help patients cope more steadily with symptom fluctuations that interfere with daily stability.”

Quick Fact: Relief for Vasomotor Symptoms
This therapy is commonly used when symptoms related to systemic hormonal imbalance, such as hot flashes, are frequent and intense.

Regulatory References

  1. DailyMed (NIH) Prescribing Information

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Postmenopausal women who still have an intact uterus.

Populations for whom use is not recommended (if applicable):

  • Lactating (breastfeeding) women (Use may decrease the quantity and quality of breast milk).

Populations for whom use is contraindicated:

  • Individuals with known, suspected, or a history of breast cancer or other estrogen-dependent cancers.
  • Individuals with undiagnosed abnormal genital bleeding.
  • Individuals with active liver disease or severe hepatic impairment.
  • Individuals with active or a history of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction (MI).
  • Individuals with known thrombophilic disorders.
  • Individuals with known or suspected pregnancy.

Age-Related and Condition Restrictions

  • Older Adults (Aged 65 and older): Use is associated with an increased risk of probable dementia.
  • Pediatric Use: The medicine is not indicated for use in children.
  • Condition-Specific Restrictions: Caution is required in patients with renal impairment due to the potential for fluid retention. Use in patients with a history of endometrial hyperplasia requires immediate withdrawal if recurrence is discovered.

Connection to the Overall Eligibility Profile

The regulatory eligibility profile for Premia is strictly defined by exclusionary criteria related to vascular risk, active hormone-sensitive cancers, and hepatic function. Use is explicitly limited to postmenopausal adult women with an intact uterus, and use is otherwise formally prohibited or restricted based on these documented criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Premia (Conjugated Estrogens/Medroxyprogesterone Acetate) is defined by pharmacokinetic effects that alter the concentration of the active ingredients, as documented in regulatory labeling.


Drug-Drug and Metabolic Interactions

Co-administration with agents that modify the CYP3A4 enzyme system can significantly affect the plasma concentrations of the estrogen component. CYP3A4 Inducers, which include medicines like Rifampin, certain anticonvulsants (e.g., Carbamazepine, Phenobarbital), and the herbal product St. John's wort, may reduce plasma concentrations of estrogens, potentially decreasing their therapeutic effects. Conversely, CYP3A4 Inhibitors, such as some antibiotics and antifungals (e.g., Ketoconazole, Itraconazole, Erythromycin), may increase estrogen concentrations. Furthermore, co-administration of Aminoglutethimide is officially documented to significantly depress the bioavailability of Medroxyprogesterone Acetate (MPA).


Substance and Population-Specific Interactions

Estrogens can increase levels of Thyroxine-Binding Globulin (TBG). This effect requires the monitoring of thyroid function for individuals co-administered with Thyroid Replacement Therapy (e.g., Levothyroxine). Co-use with Tobacco (Cigarette smoking) is classified as a major interaction and is associated with a significantly increased risk of serious cardiovascular events. Grapefruit juice is also noted as a potential inhibitor that may increase estrogen exposure.

Mechanism of Action

Premia is a combination product containing conjugated estrogens (CE) and medroxyprogesterone acetate (MPA), which exert their effects through distinct steroid hormone receptors.

Conjugated estrogens function as agonists, primarily targeting the nuclear estrogen receptors (ER-alpha and ER-beta) in various tissues. Ligand-receptor binding facilitates a conformational change, enabling the complex to interact with estrogen response elements (EREs) on DNA. This interaction modulates the transcription of specific target genes, leading to altered protein synthesis and changes in cellular proliferation and differentiation.

Medroxyprogesterone acetate acts as an agonist of the nuclear progesterone receptor (PR). Its binding induces a secretory transformation in the endometrium by decreasing nuclear estrogen receptor expression and suppressing epithelial DNA synthesis. Systemically, MPA also functions as an inhibitor of the hypothalamic-pituitary-gonadal axis, specifically by suppressing the release of gonadotropins, which leads to reduced follicular maturation and ovulation.

Dosage and Administration Information

How Premia Is Used: Official Administration Guidelines

Premia (Conjugated Estrogens/Medroxyprogesterone Acetate) is administered as an oral tablet according to specific daily dosing schedules. The use of this medication follows the general principle that the lowest effective dose is utilized for the shortest duration consistent with treatment goals, requiring periodic re-evaluation.


Administration Routes and Schedules

Premia is utilized in two primary daily dosing patterns:

  • Continuous Combined Regimen: One single combination tablet is taken orally once daily without interruption. The available strengths combine conjugated estrogens and medroxyprogesterone acetate (MPA) in fixed dosages (e.g., 0.3 mg CE / 1.5 mg MPA).

  • Sequential/Cyclic Regimen: This regimen follows a 28-day cycle. An estrogen-only tablet (CE 0.625 mg) is taken daily on Days 1 through 14. This is immediately followed by a combination tablet (CE 0.625 mg / 5.0 mg MPA) taken daily on Days 15 through 28.


Procedural Administration Contexts

The tablets are to be swallowed whole. While specific meal timing is not mandated, the absorption of the medroxyprogesterone acetate component is associated with administration with or immediately after a meal.

Special Conditions: The use of this therapy is not indicated for children. Although no specific adjustments are provided for older adults, the lowest effective dose principle is applied across all patient groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Clinical Trials

The fixed-dose combination of Drug A and Drug B was studied for the management of the symptoms of acute, non-specific diarrhea in adults. Clinical research examined whether this combination reduced the duration and frequency of loose stools, a primary focus in drug development.

Trial Design and Scope

Clinical trials focused on a combination approach. Studies focused on changes in the severity of diarrhea and overall recovery time. The combination approach was investigated in several randomized, placebo-controlled trials.

Key Findings on Clinical Outcomes

Investigators conducted Phase III trials in adult subjects experiencing acute, non-specific diarrhea. Research findings focused on key metrics, including:

  • Time to Symptom Resolution: The duration until the patient reported formed stools.
  • Total Number of Stools: The overall frequency of bowel movements during the treatment period.

Outcomes were compared to monotherapy (Drug A or Drug B alone) and placebo in controlled environments. One focus of research was on changes in fluid loss, which is measured by stool weight and consistency metrics. Studies explored whether the combination supported a reduction of discomfort, and findings examined whether it influenced associated pain and bloating.

Safety and Patient Populations Studied

Studies included adult patients generally healthy apart from the acute diarrheal episode. Research excluded patients who had specific conditions, such as severe inflammatory bowel disease, bloody diarrhea, or signs of systemic infection. Clinical studies also excluded individuals with known hypersensitivity to the active ingredients or who were pregnant or breastfeeding at the time of the trial.

Evidence in Specific Contexts

This combination was evaluated for travelers’ diarrhea in a subset of studies, with endpoints focusing on acute symptom metrics and the maintenance of daily activities. Research explored whether it supported a return toward normal gut function following the onset of symptoms.

Frequently Asked Questions (FAQ)

Common questions about Premia (FAQ)


Q: What is the main difference between Premia and other drugs for the same condition?

A: Official information describes Premia as a combination product containing both conjugated estrogens and medroxyprogesterone acetate (a progestin). This combination is specifically used for postmenopausal women who still have a uterus. Other medicines used for hormonal balance may contain different components or be administered in different ways.


Q: Can Premia be taken for other reasons besides what is on the label?

A: Regulatory documents list the specific uses for which Premia has been approved, which include treating moderate to severe symptoms of menopause and preventing postmenopausal bone loss. Official information regarding the medicine's use is strictly limited to these stated indications.


Q: How quickly does Premia start to work after taking it?

A: Clinical trials examining relief from common symptoms like hot flashes reported that treatment efficacy typically begins within the first week or two of starting therapy. The overall benefit of the therapy, relative to its risks, is a topic for periodic re-evaluation.


Q: What is the typical time frame to see the expected effect from Premia?

A: Studies and official information indicate that relief from symptoms is generally effective after one to two weeks of starting treatment. The long-term use of the treatment requires periodic clinical re-evaluation, as described in regulatory documentation.


Q: If I miss a day of Premia, what should I do?

A: The official product instruction for a missed dose is to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to adhere to the once-daily administration schedule.


Q: Is it OK to drink alcohol while taking Premia?

A: Official patient counseling information states that using alcohol with certain medicines may cause interactions. Questions about alcohol consumption can be addressed with a healthcare professional.


Q: Can Premia be crushed or split in half?

A: Premia is supplied as a tablet that is to be swallowed whole as a single daily dose. Official documents do not include instructions for cutting, crushing, or splitting the tablet.


Q: Does Premia need a special storage temperature?

A: Official labeling requires that Premia be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C (68 F to 77 F). The product must also be protected from freezing, excessive heat, and moisture.


Q: What happens if you suddenly stop taking Premia?

A: Official information states that the therapy should be immediately discontinued if a serious event occurs, such as a blood clot. In general use, the long-term necessity of the therapy should be periodically reviewed. If abrupt discontinuation is considered, contact with a healthcare professional is appropriate.


Q: Does Premia interact with herbal supplements?

A: Official drug interaction information specifically lists the herbal product St. John’s wort as a substance that may reduce the levels of the estrogen component in the body. This reduction could potentially make the medicine less effective.


Q: Does Premia affect my ability to drive or operate machinery?

A: Reported adverse reactions from clinical studies include dizziness and headache. The presence of these effects may be considered when performing tasks requiring full attention, such as driving or operating machinery.


Q: Is a small headache normal when starting Premia?

A: Yes, regulatory documents classify headache as a very common adverse reaction, meaning it occurs in ge 1/10 patients. This effect is often reported during the initial phase of therapy.


Q: Is it better to take Premia in the morning or at night?

A: The administration instruction is to take the tablet orally once daily. While the exact timing is not strictly specified, the official information notes that one component, Medroxyprogesterone Acetate, may be absorbed better if taken with or immediately after a meal.


Q: Can Premia be taken with stomach acid reducers?

A: Official drug interaction documents primarily describe interactions related to the CYP3A4 enzyme system (a liver process for drug breakdown). Interactions with common stomach acid reducers are not specifically listed. The use of these substances alongside Premia is a suitable topic for discussion with a healthcare professional.


Q: What happens if a healthy person accidentally takes Premia?

A: Official overdosage information notes that symptoms may include nausea, vomiting, or vaginal bleeding or spotting. If accidental ingestion occurs, contact with a healthcare professional is appropriate.


Q: Can Premia make you feel anxious or nervous?

A: Regulatory documents list anxiety and depression among the reported adverse reactions. Any changes in mood can be discussed with a healthcare professional.


Q: How is Premia removed from the body?

A: The active components are extensively processed in the liver (a process called metabolism) and then mostly eliminated from the body in the urine.


Q: What is the likelihood of a severe allergic reaction to Premia?

A: Official regulatory documents warn that the medicine may cause a serious allergic reaction, including anaphylaxis and angioedema (swelling), which can be life-threatening. The exact frequency of a severe reaction is not explicitly quantified in the official side effect tables.


Q: Is it normal to feel a change in appetite after starting Premia?

A: The progestin component (Medroxyprogesterone Acetate) has been officially associated with reports of both increased appetite and decreased appetite. This means a change in appetite can be a possibility when starting this therapy.

How should Premia be stored and disposed of?

Official Storage Requirements

Premia (conjugated estrogens and medroxyprogesterone acetate tablets) must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C (86 F). The product must be protected from freezing, excessive heat, and moisture.

Tablets should be kept in their original, closed container or blister packaging and stored away from direct light. Like all medicines, Premia is required to be stored out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Premia must be conducted according to local regulatory requirements for pharmaceutical waste. Individuals should consult a healthcare professional or local authority on the proper way to discard any remaining tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Premia found in:

A-Z Index: